small molecule

VYALEV

FOSCARBIDOPA; FOSLEVODOPA

Loss of exclusivityJune 2040latest FDA-listed patent expiry

CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand name	VYALEV
Active ingredient	FOSCARBIDOPA; FOSLEVODOPA
Strength	120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML)
Dosage form	SOLUTION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	October 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
12251365	June 2040	use U-4030
9446059	October 2035	substance, product
10174061	October 2035	product
10730895	October 2035	substance

Regulatory exclusivity

Code	Expires
NP	October 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from AbbVie Inc.